Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence

Transfusion

Volumn 56, Issue 11, 2016, Pages 2662-2667

  Stack, Gary ^a,b   Tormey, Christopher A ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIGEN;

ALLOIMMUNIZATION; ANEMIA; ANTIBODY INDUCTION; ANTIBODY SCREENING; ARTICLE; BLOOD GROUP ABO SYSTEM; CHRONIC DISEASE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; EVANESCENCE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENERAL HOSPITAL; HUMAN; HUMAN CELL; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAL RECORD; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; ADVERSE EFFECTS; BIOSYNTHESIS; BLOOD; BLOOD GROUP INCOMPATIBILITY; CLINICAL PRACTICE; IMMUNOLOGY; KINETICS; RETROSPECTIVE STUDY; STANDARDS; TIME FACTOR; TRANSFUSION REACTION;

BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; HUMANS; ISOANTIBODIES; KINETICS; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSFUSION REACTION;

EID: 84979079529     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13704     Document Type: Article

References (23)

1. Pineda AA, Taswell HF, Brzica SM Jr. Transfusion reaction. An immunologic hazard of blood transfusion. Transfusion 1978;18:1–7.
2. Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev 2014;28:137–44.
3. Vidler JB, Gardner K, Amenyah K, et al. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol 2015;169:746–53.
4. Transfusion/donation fatalities [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; last updated 2015 Dec 12 [cited 2016 Feb 22]. Available from: http://www.fda.gov/biologicsbloodvaccines/safetyavailability/reportaproblem/transfusiondonationfatalities/default.htm.
5. U.K. Serious Hazards of Transfusion (SHOT) Steering Group. SHOT annual reports and summaries [Internet]. Manchester (UK): SHOT Office; [cited 2016 Feb 22]. Available from: http://www.shotuk.org/shot-reports/.
6. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996;71:216–20.
7. Gunson HH, Stratton H, Cooper DG, et al. Primary immunization of Rh-negative volunteers. Br Med J 1970;1:593–5.
8. Contreras M, Mollison PL. Failure to augment primary Rh immunization using a small dose of “passive” IgG anti-Rh. Br J Haematol 1981;49:371–81.
9. Harm SK, Yazer MH, Monis GF, et al. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014;141:256–61.
10. Ramsey G, Larson P. Loss of red cell alloantibodies over time. Transfusion 1988;28:162–5.
11. Ramsey G, Smietana SJ. Long-term follow-up testing of red cell alloantibodies. Transfusion 1994;34:122–4.
12. Reverberi R. The persistence of red cell alloantibodies. Blood Transfus 2008;6:225–34.
13. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431–7.
14. Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000;40:1127–31.
15. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009;49:505–12.
16. Alves VM, Martins PR, Soares S, et al. Alloimmunization screening after transfusion of red blood cells in a prospective study. Rev Bras Hematol Hemoter 2012;34:206–11.
17. Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008;48:2069–76.
18. Chassin MR. Is health care ready for six sigma quality? Milbank Q 1998;76:565–91.
19. Quest Diagnostics. What is six sigma quality at Quest Diagnostics? [Internet]. 2000-2016 [cited 2016 Mar 25]. Available from: http://www.questdiagnostics.com/home/about/operations/quality/six-sigma.html.
20. Hoeltge GA, Domen RE, Rybicki LA, et al. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch Pathol Lab Med 1995;119:42–5.
21. Spielmann W, Seidl S. Prevalence of irregular red cell antibodies and their significance in blood transfusion and antenatal care. Vox Sang 1974;26:551–9.
22. Walker RH, Lin DT, Hartrick MB. Alloimmunization following blood transfusion. Arch Pathol Lab Med 1989;113:254–61.
23. Winters JL, Pineda AA, Gorden LD, et al. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion 2001;41:1413–20.